Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 20, 2026 · Filed Apr 22, 2026
The CEO of Biocardia paid $738 out of pocket for Biocardia shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$738
Shares × reported transaction price
<$25K
+0.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 7 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2024 ($493K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2025-11-03. The proxy names Peter Altman as CEO for that year. A size comparison, not a judgement
27 days after results of Mar 24, 2026, 25 days before results of May 15, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1.25 on Apr 20, 2026, 15% above its 52-week low and 60% below its high, after a 6% rise over the previous 30 trading days
52-week range $1.09 (Feb 4, 2026) to $3.14 (Apr 30, 2025), 8% of the way up, from 251 adjusted closes. 30 trading days earlier: $1.18 on Mar 6, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.6% | +1.4% | −4.0% |
| 30 days | −22.1% | +6.0% | −28.1% |
| 90 days | −22.6% | +5.5% | −28.1% |
| 180 days | −11.1% | +8.6% | −19.7% |
Past results only. Not a forecast.
Insider buying
Traded May 19 · filed 2 days later
The CEO of Biocardia paid $190 out of pocket for Biocardia shares.
Insider buying
Traded May 20 · filed 1 day later
The CEO of Biocardia paid $1.4K out of pocket for Biocardia shares.
Insider buying
Traded May 18 · filed 1 day later
The CEO of Biocardia paid $5.2K out of pocket for Biocardia shares.
Peter Altman, President and CEO's past purchases, 90 days after disclosure: 38 buys, median −9.0 pts vs S&P 500, beat it 13 of 38 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.